AI Article Synopsis

  • Centralized drug procurement, like China's 2018 CVBP, aims to ease healthcare costs and enhance the pharmaceutical industry.
  • Research on the impact of this procurement method shows it significantly boosts R&D investment among pharmaceutical firms, especially those with high marketing expenses.
  • The study utilizes data from listed firms in China's A-share market, confirming the findings through various robust testing methods, thus offering valuable insights for governments and firms on fostering innovation.

Article Abstract

Centralized drug procurement is a common practice worldwide to relieve the healthcare burden and promote high-quality development in the pharmaceutical industry. However, scholars have not yet reached an agreement on whether centralized procurement can facilitate the innovation activities of pharmaceutical firms. China's centralized volume-based procurement (CVBP) implemented in 2018 provides an ideal quasi-natural experiment to evaluate the effect of centralized procurement on the R&D investment of the firms. Drawing data from listed manufacturing firms in China's A-share market (2015-2020), the results from a difference-in-differences analysis with different model specifications indicate that the CVBP significantly promotes the pharmaceutical manufacturing firms' R&D investment. Moreover, the positive effect of the CVBP on R&D investment is stronger in pharmaceutical manufacturing firms with high marketing expenses. A series of robustness tests including the parallel trend test, placebo test, and the PSM-DID analysis show that our findings are solid. This paper advances our understanding of centralized procurement in emerging markets and provides new insights into how governments and pharmaceutical manufacturing firms can strengthen innovation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698415PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0315811PLOS

Publication Analysis

Top Keywords

pharmaceutical manufacturing
16
r&d investment
16
centralized procurement
12
manufacturing firms
12
centralized volume-based
8
volume-based procurement
8
manufacturing firms'
8
firms' r&d
8
firms china's
8
procurement
6

Similar Publications

Numerous commercially available biopharmaceuticals are frozen or freeze-dried in vials. The temperature at which ice nucleates and its distribution across vials in a batch is critical to the design of freezing and freeze-drying processes. Here we study experimentally how the level of particulate impurities - a key parameter in pharmaceutical manufacturing - affects the ice nucleation behavior.

View Article and Find Full Text PDF

This study used Raman and near-infrared (NIR) spectroscopy to monitor small real-time changes in powder blends and tablets in low-dose pharmaceutical formulations. The research aims to enhance process analytical technology (PAT) in pharmaceutical manufacturing, ensuring high-quality and uniform products with applications to produce drugs with narrow therapeutic indices (NTI). The study utilizes Raman and NIR spatially resolved spectroscopy (SRS) techniques to monitor a moderate cohesive material's active pharmaceutical ingredient (API) concentrations during manufacturing.

View Article and Find Full Text PDF

A rapid chemical reprogramming system to generate human pluripotent stem cells.

Nat Chem Biol

January 2025

MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences and MOE Engineering Research Center of Regenerative Medicine, School of Basic Medical Sciences, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.

Chemical reprogramming enables the generation of human pluripotent stem (hCiPS) cells from somatic cells using small molecules, providing a promising strategy for regenerative medicine. However, the current method is time consuming, and some cell lines from different donors are resistant to chemical induction, limiting the utility of this approach. Here, we developed a fast reprogramming system capable of generating hCiPS cells in as few as 10 days.

View Article and Find Full Text PDF

Carbon nanotubes (CNTs) has emerged as a promising nanomaterial with a wide range of potential applications due to their unique structural, mechanical, electrical, and thermal properties. However, numerous obstacles must be overcome for CNTs to be used successfully, including low solubility, aggregation, and a lack of specialized functions. Diverse techniques have been developed for the manufacture, purification, and functionalization of CNTs in order to overcome these issues.

View Article and Find Full Text PDF

The rapid development of delivery systems for cosmetics has revealed two critical challenges in the field: enhancing the solubility of active ingredients and ensuring the stability of natural materials used in cosmetics. Nanoemulsion technology has emerged as an indispensable solution for addressing these challenges, not only enhancing the stability of cosmetics but also improving the solubility of pharmaceuticals and active ingredients with poor solubility. Nanoemulsion formulations have reinforced stability and amended the bioavailability of hydrophobic drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!